Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 7/2009

01-10-2009 | Research Paper

Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells

Authors: Kyung Hee Lee, Jae-Ryong Kim

Published in: Clinical & Experimental Metastasis | Issue 7/2009

Login to get access

Abstract

The potential role of hepatocyte growth factor (HGF) in the regulation of angiogenesis factors in hepatoma cells is not widely appreciated. We investigated the role of HGF-induced activation of a transcription factor, Egr-1, in the expression of pro-angiogenic factors. Genes associated with angiogenesis induced by HGF were screened by using cDNA microarray technology in hepatocellular carcinoma cell lines, HepG2 and Hep3B. Expression levels of Egr-1, vascular endothelial growth factor (VEGF), and interleukin (IL)-8 were further confirmed by real time RT-PCR and Western blot analysis. Roles of Egr-1 in the levels of HGF-induced up-regulations of VEGF and IL-8 were measured by knockdown of Egr-1 with Egr-1 shRNA and chromatin immunoprecipitation assay. The levels of Egr-1, VEGF and IL-8 were up-regulated in cells treated with HGF. HGF-induced up-regulations of Egr-1, VEGF, and IL-8 were inhibited by the pretreatment with an MEK inhibitor, PD098059. HGF-induced up-regulation of VEGF and IL-8 were repressed by Egr-1 knockdown. HGF enhanced the binding activity of Egr-1 to the VEGF promoter in control cells, but not in the Egr-1-shRNA cells. No constitutive and inducible Egr-1 binding activities to the IL-8 promoter were observed in control and Egr-1-shRNA cells. Egr-1 knockdown reduced the luciferase activities increased by HGF not in the IL-8 promoter, but in the VEGF promoter. Egr-1 might play an important role in the up-regulation of VEGF and IL-8 induced by HGF and contribute to HGF-mediated angiogenesis, which might be promising targets for hepatocellular carcinoma therapy.
Literature
1.
Jeffers M, Rong S, Vande GF (1996) Enhanced tumorigenicity and invasion—metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16:1115–1125PubMed
2.
3.
Vejchapipat P, Tangkijvanich P, Theamboonlers A, Chongsrisawat V, Chittmittrapap S, Poovorawan Y (2004) Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol 39:1182–1188. doi:10.​1007/​s00535-004-1469-8 CrossRefPubMed
4.
Brian W, Xin PY, Tin LL, Lorena B, Ning TY, Joshua GC, Carter VW, Zhong C (2005) Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res 65(16):7071–7080. doi:10.​1158/​0008-5472.​CAN-04-0989 CrossRef
5.
Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C (2003) Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 106:34–44. doi:10.​1002/​ijc.​11188 CrossRefPubMed
6.
Riedel F, Gotte K, Schwalb J, Wirtz H, Bergler W, Hormann K (2000) Serum levels off vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 257:332–336. doi:10.​1007/​s004059900208 CrossRefPubMed
7.
Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van WC (2001) Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3 K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61:5911–5918PubMed
8.
Zhang YW, Su Y, Volpert OV, Vande Woude GF (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100:12718–12723. doi:10.​1073/​pnas.​2135113100 CrossRefPubMed
9.
Bancroft CC, Chen Z, Yeh J et al (2002) Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3 K and MEK signal kinases on NF-kB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99:538–548. doi:10.​1002/​ijc.​10398 CrossRefPubMed
10.
Bancroft CC, Chen Z, Dong G et al (2001) Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kB signal pathways. Clin Cancer Res 7:435–442PubMed
11.
Sukhatme VP, Cao X, Chang LC, Tsai-Morris C-H, Stamenkovich D, Ferreira PCP, Cohen DR, Edwards SA, Shows TB, Curran T, Le Beau MM, Adamson ED (1988) A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell 53:37–43. doi:10.​1016/​0092-8674(88)90485-0 CrossRefPubMed
12.
Chavrier P, Zerial M, Lemaire P, Almendral J, Bravo R, Charnay P (1988) A gene encoding a protein with zinc fingers is activated during G0/G1 transition in cultured cells. EMBO J 7:29–35PubMed
13.
Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE (2005) Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 67:356–364. doi:10.​1124/​mol.​104.​005108 CrossRefPubMed
14.
Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM (2003) Transcription Factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 9:1026–1032. doi:10.​1038/​nm905 CrossRefPubMed
15.
Yang SH, Kim JS, Oh TJ, Kim MS, Lee SW, Woo SK, Cho HS, Choi YH, Kim YH, Rha SY, Chung HC, An SW (2003) Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Int J Oncol 22:741–750PubMed
16.
Kyung HL, Eun YC, Min KK, Byung IJ, Tae NK, Sang WK, Sun KS, Jung HK, Jae RK (2006) Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines. Exp Mol Med 38(1):27–35
17.
Schug J, Overton GC (1977) TESS: transcription element search software. Technical Report CBIL-TR-1997-1001-v0.0 of the Computational Biology and Informatics Laboratory, School of Medicine, University of Pennsylania
18.
Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629–641. doi:10.​1083/​jcb.​119.​3.​629 CrossRefPubMed
19.
20.
Lim RW, Varnum BC, Herschman HR (1987) Cloning of tetradecanoyl phorbol ester-induced ‘primary response’ sequences and their expression in density-arrested Swiss 3T3 cells and a TPA non-proliferative variant. Oncogene 1(3):263–270PubMed
21.
Cao XM, Koski RA, Gashler A et al (1990) Identification and characterization of the Egr-1 gene product, a DNA-binding zinc finger protein induced by differentiation and growth signals. Mol Cell Biol 10:1931–1939PubMed
22.
Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konin H, Weg-Remers S, Ponta H (2000) CD44 acts both as a growth-and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci 910:106–120PubMedCrossRef
23.
Hyun AH, Gu L, Hee JK, Yonh GK, Sung HB, Jae LL, Kyung HL, Dong SK (2003) Overexpression of c-Met protein in gastric cancer and role of uPAR as a therapeutic target. Cancer Res Treat 35(1):9–15
24.
Juan AR, Glenn M (2003) Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1. Cancer Res 63:1576–1582
25.
Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B, Mmuller KM (1998) Hepatocyte growth factor/scatter factor and its receptor c-met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 124:291–296. doi:10.​1007/​s004320050171 CrossRefPubMed
26.
27.
28.
Silverman ES, Khachigian LM, Lindner V, Williams AJ, Collins T (1997) Inducible PDGF A-chain transcription in smooth muscle cells is mediated by Egr-1 displacement of Sp1 and Sp3. Am J Physiol 273:H1415–H1426PubMed
Metadata
Title
Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells
Authors
Kyung Hee Lee
Jae-Ryong Kim
Publication date
01-10-2009
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 7/2009
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-009-9266-7

Other articles of this Issue 7/2009

Clinical & Experimental Metastasis 7/2009 Go to the issue

Original Research

Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation

Research Paper

Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma

Research Paper

Impact of Octreotide and SOM-230 on liver metastasis and hepatic lipidperoxidation in ductal pancreatic adenocarcinoma in Syrian Hamster

Research Paper

Management of small pulmonary nodules in patients with sarcoma

Research Paper

Establishment and characterization of a new highly metastatic human osteosarcoma cell line

Research Paper

High expression of Snail mRNA in blood from hepatocellular carcinoma patients with extra-hepatic metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits